Montmorillonite Toxicity
Identifiers
Functions
Hazards
What are the material safety considerations for Montmorillonite?
Montmorillonite presents primarily irritant hazards, with GHS classifications for skin irritation (H315), serious eye irritation (H319), and respiratory irritation (H335), all under a Warning signal word. Acute toxicity data show an intravenous LD50 of 35 mg/kg in rats, while oral dosing at 5 g/kg and dermal application at 2 g/kg in animal studies did not produce lethal effects. Short-term exposure causes mild eye and skin irritation, and inhalation may lead to coughing. These findings indicate that the material is not acutely toxic by oral or dermal routes but requires caution for irritant and inhalation risks in occupational settings.
How should hazard classifications and toxicology findings for Montmorillonite be interpreted together?
The GHS irritant classifications and toxicology data should be interpreted as complementary: the classifications define the primary hazard profile (skin, eye, respiratory irritation), while the acute toxicity studies establish that lethality is not a major concern for oral or dermal exposure. The intravenous LD50 of 35 mg/kg is route-specific and not directly relevant to typical cosmetic or industrial exposure scenarios. The Cosmetic Ingredient Review concluded Montmorillonite is safe in cosmetics at current use concentrations, with a qualification that data are insufficient for products that may be incidentally inhaled. This means formulators should prioritize irritation and inhalation risk management over systemic toxicity concerns.
Which exposure routes, dose contexts, or effects are material for Montmorillonite?
The material exposure profile centers on inhalation, skin contact, and eye contact. Inhalation is a confirmed absorption route, with short-term exposure causing cough and respiratory irritation, and long-term exposure potentially affecting the lungs, possibly leading to fibrosis. Skin contact produces redness, and eye contact causes redness and pain. Acute oral exposure at 5 g/kg and dermal exposure at 2 g/kg in rats and rabbits, respectively, did not result in lethality, indicating low systemic toxicity via these routes. The key material exposure context is therefore occupational inhalation of dust, particularly in powder handling, rather than consumer dermal application.
Which handling and risk-management measures are relevant for Montmorillonite?
Handling measures should focus on preventing inhalation and minimizing skin and eye contact. Storage in a tightly closed container in a dry, well-ventilated place is required, as Montmorillonite is hygroscopic and absorbs atmospheric water. For occupational settings, dust control measures such as local exhaust ventilation and respiratory protection are implied by the inhalation hazard and the potential for lung effects. Given the GHS irritant classifications, protective gloves and eye protection are advisable to prevent skin and eye irritation. The CIR qualification regarding incidental inhalation in cosmetic products suggests that powder forms intended for aerosolization or loose application require additional safety assessment.
Which safety evidence gaps should be resolved before making decisions about Montmorillonite?
The primary evidence gap is the lack of sufficient data to determine safety for products that may be incidentally inhaled, as noted by the Cosmetic Ingredient Review. This is decision-relevant for formulators considering Montmorillonite in loose powders, sprays, or other inhalable formats. Additionally, no occupational exposure limits are available in the evidence, which limits quantitative risk assessment for workplace settings. Long-term inhalation effects are inferred from related bentonite data rather than direct Montmorillonite studies, creating uncertainty about fibrosis risk. Resolving these gaps would require inhalation toxicity studies specific to Montmorillonite and establishment of exposure thresholds.